Tacrolimus as a therapeutic option in patients with acquired neuromyotonia

• Published in: Journal of neuroimmunology 2021-06, Vol.355, p.577569-577569, Article 577569
• Main Authors: Liu, Chenchen, Ji, Suqiong, Bi, Zhuajin, Shang, Ke, Gao, Huajie, Bu, Bitao
• Format: Article
• Language: English
• Subjects: CASPR2; IgLON5; LGl1; Neuromyotonia; Sjogren's syndrome; Tacrolimus
• ISSN: 0165-5728; 1872-8421
• DOI: 10.1016/j.jneuroim.2021.577569

To analyze the clinical characteristics and outcomes of patients diagnosed with acquired neuromyotonia and who were treated with tacrolimus. A single center, retrospective study was performed on patients with acquired meuromyotonia whose treatment included tacrolimus. The clinical information, antibody tests, and electromyography results were reviewed. The Numeric Rating Scale for pain and modified Rankin scale were used to quantify outcomes. This study included four patients who presented with fasciculation or myokymia in their limbs. Electromyography suggested peripheral nerve hyperexcitability. Autoantibodies including contactin-associated protein 2 (CASPR2), leucine-rich glioma inactivated protein 1 (LGl1) or IgLON5 antibody were detected in three patients, and another patient had Sjogren's syndrome. Initial treatment included membrane-stabilizing drugs and/or corticosteroids. Tacrolimus was administered at a dose of 3 mg once daily to all patients. All patients showed clinical improvement after the treatment. No recurrence was observed after gradual tapering or discontinuation of therapy during follow-up. Tacrolimus may be a therapeutic option for acquired neuromyotonia. Further studies on tacrolimus in larger patient cohort should be performed. [Display omitted] •Except for LGI1 and CASPR2, acquired neuromyotonia can be associated with other autoantibodies such as IgLON5.•Neuromyotonia can be associated with Sjogren's syndrome.•Tacrolimus may be a therapeutic option for acquired neuromyotonia.